FDA Should Undo Incentives For Single-Use Products, Device Reprocessing Expert Says

Medtech Insight sat down with Dan Vukelich, president and CEO of the Association of Medical Device Reprocessors, to discuss the need for sustainable alternatives to limit waste from medical devices.

• Source: Shutterstock

A majority of Dan Vukelich’s time is used educating manufacturers on the regulatory incentives against reprocessing devices.

“Single-use labeling isn't decided by FDA, it's up to the manufacturer,” the president and CEO of the Association of Medical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ESG

Urban Wastewater Directive: AESGP Requests Intervention In EFPIA’s Legal Action

 
• By 

AESGP has formally submitted a request to the General Court of the European Union to intervene in the European Federation of Pharmaceutical Industries and Association’s legal action against the revised EU Urban Wastewater Directive.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

 
• By 

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.

Pharma Deutschland Seeks To Enter Urban Wastewater Legal Dispute

 
• By 

The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.

More from HBW Insight

NDA User Fees Increasing 8.6% As FDA Projects More Applications But Fewer Sponsor Meetings

 

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.

US Consumer Health Q2 Earnings Preview: Baggage Comes With Costs, Expectations

 

In addition to impact from tariffs and executive suite changes, recent baggage for firms in the space include Perrigo divesting its branded Dermacosmetics business and Church & Dwight acquiring Touchland hand sanitizer brand.

Expanded Distribution In US Helps Drive Up BioGaia Sales

 
• By 

Swedish probiotics player BioGaia is reaping the benefits of increased marketing investments and distribution in the US.